Leuvate

Mechanism of Action

Leucine is sensed intracellularly by Sestrin2, which releases GATOR2 to activate the Rag GTPases and recruit mTORC1 to the lysosomal surface. Activated mTORC1 phosphorylates p70S6K1 and 4E-BP1, driving cap-dependent translation initiation and increasing myofibrillar protein synthesis for ~2–3 h. The remaining eight EAAs (isoleucine, valine, lysine, threonine, methionine, phenylalanine, histidine, tryptophan) supply the substrate — without them, the translational machinery runs out of building blocks and the anabolic response collapses. BCAAs alone (leucine + isoleucine + valine) transiently raise signalling but cannot sustain net MPS because they compete with the other EAAs for transport and cannot supply the full amino acid pool.

Physiological Role

Delivers all nine essential amino acids — those the body cannot synthesise — in a leucine-forward ratio. EAAs are rate-limiting for muscle protein synthesis, connective tissue turnover, immune-cell proliferation, neurotransmitter precursor supply (phenylalanine → tyrosine → catecholamines; tryptophan → serotonin), and one-carbon metabolism (methionine). Exact Leuvate composition and inter-amino ratios are not publicly disclosed by PVL.

Primary Pathways

Performance / Health Relevance

Two commercial use-cases, each with its own honest read. • As an additive to protein: the stronger of the two uses and the only one with independent evidence behind it. A base of ~6–15 g whole protein plus enough leucine-enriched EAA to bring the serving to ~2.5–3 g leucine can match a full 25 g whey dose for resting MPS (Churchward-Venne 2014). What matters is the leucine number, not the blend weight. Two ceilings keep this honest: (a) a full 25–40 g protein dose still wins for the post-training synthesis response — the leucine top-up rescues the resting response, not the trained one; and (b) once the base already carries enough leucine, adding more does nothing. So the lever pays on small or plant-forward servings and is close to pointless bolted onto a full whey shake. • As a stand-alone EAA: a leucine-rich EAA dose triggers MPS off a fraction of the calories and bulk of a protein shake, and free aminos appear in plasma faster than whole protein — useful intra-workout, for older adults, or when appetite/intake is low. It does not give the slow amino drip-feed, satiety, or wider nutrition of real protein, so it is an add-on, not a replacement. Commercially the shelf is crowded and undifferentiated: as a stand-alone, Leuvate is functionally the same as Amino9, a self-blended nine-EAA, or PVL's own separately labelled EAA — you would be paying for the name and a borrowed study. • The long-term caveat: nearly all supporting trials measure acute (2–6 h) synthesis, not months of muscle on the body. Longer leucine-supplementation trials in people already eating enough protein have mostly come up empty. Leuvate is a lever for under-fed, low-dose or plant-based formats — not a growth ingredient for people already hitting their protein numbers. • Against the alternatives: versus a self-blended leucine + EAA mix, Leuvate offers nothing beyond a trademark that formulators cannot license anyway — the self-blend delivers the same effect at the lowest cost with full control of the leucine ratio. Versus Velositol, Leuvate is cheaper to run and works on a different mechanism (leucine trigger vs insulin-driven amino-acid uptake), though Velositol carries its own branded human study and a real 2 g inclusion cost. Versus an acid-stable protease, it is doing a different job entirely — triggering synthesis rather than speeding absorption — and the protease is the cheaper add-on. All of these lift usable protein, and none of them supports an authorised claim on a GB label.

Side Effects

• •Occasional mild GI discomfort (bloating, loose stool) from high single doses of free-form aminos
• •Bitter/metallic taste from free-form leucine, isoleucine and valine — usually masked by flavour system
• •Transient rise in plasma ammonia at very high acute EAA doses (uncommon at sports-nutrition levels)

Contraindications

• Phenylketonuria (PKU) — contains phenylalanine
• Maple syrup urine disease (MSUD) — branched-chain amino acid metabolism defect
• Advanced chronic kidney disease unless supervised by a renal dietitian
• Advanced hepatic encephalopathy (nitrogen load consideration)

Drug Interactions

• •Levodopa — large neutral amino acids (phenylalanine, leucine, isoleucine, valine, tryptophan) compete for the LAT1 transporter at the blood–brain barrier and can blunt levodopa absorption; separate dosing by ≥1 h
• •No other clinically significant interactions established at typical sports-nutrition doses

Who Should Avoid

• •Pregnancy or breastfeeding without professional guidance
• •Anyone on medication or with a medical condition without clinician sign-off
• •Individuals following a very low-protein medical diet

Monitoring

No routine monitoring required in healthy adults at typical sports-nutrition doses. In people with reduced renal function, monitor eGFR and urinary urea if EAA intake is chronic and high (>20 g/day on top of dietary protein).